Clinical trial NCT00601718 (phase 1/phase 2, status: completed)
Conditions: adult nasal type extranodal nk/t-cell lymphoma, anaplastic large cell lymphoma, angioimmunoblastic t-cell lymphoma, contiguous stage ii mantle cell lymphoma, cutaneous b-cell non-hodgkin lymphoma, extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue, nodal marginal zone b-cell lymphoma, noncontiguous stage ii mantle cell lymphoma, recurrent adult burkitt lymphoma, recurrent adult diffuse large cell lymphoma, recurrent adult diffuse mixed cell lymphoma, recurrent adult diffuse small cleaved cell lymphoma, recurrent adult grade iii lymphomatoid granulomatosis, recurrent adult hodgkin lymphoma, recurrent adult immunoblastic large cell lymphoma, recurrent adult lymphoblastic lymphoma, recurrent cutaneous t-cell non-hodgkin lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent mycosis fungoides/sezary syndrome, recurrent small lymphocytic lymphoma, splenic marginal zone lymphoma, stage i cutaneous t-cell non-hodgkin lymphoma, stage i mantle cell lymphoma, stage i mycosis fungoides/sezary syndrome, stage ii cutaneous t-cell non-hodgkin lymphoma, stage ii mycosis fungoides/sezary syndrome, stage iii cutaneous t-cell non-hodgkin lymphoma, stage iii mantle cell lymphoma, stage iii mycosis fungoides/sezary syndrome, stage iv cutaneous t-cell non-hodgkin lymphoma, stage iv mantle cell lymphoma, stage iv mycosis fungoides/sezary syndrome, waldenström macroglobulinemia
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, G47.13, J01.41, K11.22, K12.0, N96, F33.8, G03.2, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, D68.61, D69.41, D81.4, E24.1, E26.01, E26.81, E34.0, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, D68.61, D69.41, D81.4, E24.1, E26.01, E26.81, E34.0, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, D68.61, D69.41, D81.4, E24.1, E26.01, E26.81, E34.0, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, D68.61, D69.41, D81.4, E24.1, E26.01, E26.81, E34.0, C88.0
Drugs: vorinostat, ifosfamide, carboplatin, etoposide
SMILES: ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1, N[C@@H](CCCNC(N)=N)C(O)=O, N[C@@H](CCCNC(N)=N)C(O)=O, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have relapsed or primary refractory lymphoid malignancy (including
             B-cell, T-cell, or Hodgkins disease), or untreated T-NHL or MCL

          -  Patients with other lymphomas that have not received any prior therapy and are not
             candidates for anthracycline-based therapies, are eligible with PI review and approval

          -  Revised European American classification (REAL), or World Health Organization (WHO)
             classification of patient's malignancies must be provided

          -  Patients must have measurable disease defined as lesions that can be accurately
             measured in two dimensions by computed tomography (CT), magnetic resonance imaging
             (MRI), medical photograph (skin or oral lesion), plain x-ray, or other conventional
             technique and a greatest transverse diameter of 1 cm or greater; or palpable lesions
             with both diameters >= 2 cm

          -  Patients must have a bone marrow aspirate and biopsy within 28 days of enrollment and
             no intervening anticancer therapy

          -  Patients must have a CT of chest, abdomen, and pelvis within 28 days of enrollment;
             patients with evidence of adenopathy in the neck must have a CT of neck

          -  Patients should not have evidence of active central nervous system lymphoma

          -  Electrocardiogram (EKG) must be free of any arrhythmias (excluding sinus arrhythmia or
             infrequent premature ventricular contractions)

          -  Patients must have a Southwest Oncology Group (SWOG) performance status of 0, 1, or 2

          -  Absolute neutrophil count (ANC) >= 1,500/mm^3

          -  Serum creatinine < 1.5 mg/dl or creatinine clearance greater than 60/ ml per minute by
             the following formula (all tests must be performed within 28 days prior to
             registration)

          -  Total bilirubin < 1.5 times upper limit of normal, aspartate aminotransferase (AST) <
             5 times upper limit of normal

          -  Patients must have a serum lactate dehydrogenase (LDH) performed within 14 days prior
             to registration

          -  All patients must be informed of the investigational nature of this study and have
             given written consent in accordance with institutional and federal guidelines

          -  Patients must be anticipated to complete at least 2 cycles of chemotherapy

          -  Platelets >= 100,000/mm^3 (without transfusion)

        Exclusion Criteria:

          -  Patients known to be human immunodeficiency virus (HIV) positive

          -  Pregnant or nursing women; men or women of reproductive potential may not participate
             unless they have agreed to use an effective contraceptive method

          -  Patients with other prior malignancies except for adequately treated basal cell
             carcinoma, squamous cell carcinoma of the skin, cervical cancer in situ, or other
             cancer from which the patient has been disease free for 5 years or greater, unless
             approved by the protocol Chair or Co-Chair

          -  Patients that are refractory (i.e. not responded or progressed within 6 months) to a
             carboplatin, cisplatin, ifosfamide, or etoposide-based regimen-based regimen

          -  Patients that have other medical conditions that would contraindicate treatment with
             aggressive chemotherapy (including active infection, uncontrolled hypertension,
             congestive heart failure, unstable angina pectoris, or myocardial infarction within
             the past 6 months, or uncontrolled arrhythmia)

          -  Patients with a history of impaired cardiac status (including history of severe
             coronary artery disease, cardiomyopathy, congestive heart failure or arrhythmia); if
             the patient's history is questionable, a measurement of left ventricular ejection
             fraction should be obtained within 42 days prior to registration; patients with left
             ventricular ejection fraction < 50% are not eligible

          -  Autologous or allogeneic transplantation within 12 months or radioimmunotherapy within
             6 months of registration

          -  No concurrent treatment with valproic acid or on valproic acid within 2 weeks of study
             enrollment

          -  No prior treatment with histone deacetylase inhibitors

          -  No concurrent therapy for this malignancy